Session » Vasculitis - Poster III: Rarer Vasculitides

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2969

10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis

9:00AM-11:00AM: Abstract Number: 2973

A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions

9:00AM-11:00AM: Abstract Number: 2979

a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome

9:00AM-11:00AM: Abstract Number: 2947

Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients

9:00AM-11:00AM: Abstract Number: 2974

An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center

9:00AM-11:00AM: Abstract Number: 2954

Anti-IL6-R Tocilizumab in Refractory Uveitis Associated with BehçEt’s Disease. Multicenter Study of 11 Patients

9:00AM-11:00AM: Abstract Number: 2961

Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?

9:00AM-11:00AM: Abstract Number: 2966

Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?

9:00AM-11:00AM: Abstract Number: 2959

Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up

9:00AM-11:00AM: Abstract Number: 2940

Bechet’s Disease and Sleep Quality in Korean Patients

9:00AM-11:00AM: Abstract Number: 2963

BehçEt’s Disease in Children: Eastern Mediterranean Experience

9:00AM-11:00AM: Abstract Number: 2955

Biologic Therapy in Severe Peripheral Ulcerative Keratitis (PUK). Multicenter Study of 27 Patients

9:00AM-11:00AM: Abstract Number: 2971

Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey

9:00AM-11:00AM: Abstract Number: 2950

Cogan Syndrome: Treatment and Outcome from French Nationwide Retrospective Study and Literature Review of 62 Patients

9:00AM-11:00AM: Abstract Number: 2953

Comparison of Patient Outcomes in Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome

9:00AM-11:00AM: Abstract Number: 2952

Differentiation Between Neurosarcoidosis and Primary CNS Vasculitis Based on Clinical and Cerebrospinal Fluid Parameters

9:00AM-11:00AM: Abstract Number: 2976

Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease

9:00AM-11:00AM: Abstract Number: 2968

Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients

9:00AM-11:00AM: Abstract Number: 2962

Expression Profile of Chemokines Is Skewed to Th17/Th22 Recruitment in Circulation of Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2948

Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study

9:00AM-11:00AM: Abstract Number: 2958

Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden

9:00AM-11:00AM: Abstract Number: 2967

Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise

9:00AM-11:00AM: Abstract Number: 2970

Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database

9:00AM-11:00AM: Abstract Number: 2975

Increase of Sacroiliitis By Follow-up and Routine CT in Patients with Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2960

Increased Post-Thrombotic Syndrome Is Unassociated with Anticoagulant Use in Vascular Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2980

Inflammation As an Under-Recognized Cause of Ascending Aortic Aneurysms: A Single-Center Clinical and Pathological Study of 53 Cases over 6 Years

9:00AM-11:00AM: Abstract Number: 2946

Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci

9:00AM-11:00AM: Abstract Number: 2965

Late-Onset Relapse in Patients with Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 2941

Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients

9:00AM-11:00AM: Abstract Number: 2956

Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases

9:00AM-11:00AM: Abstract Number: 2951

Patient Outcomes in Primary Angiitis of the Central Nervous System

9:00AM-11:00AM: Abstract Number: 2957

Primary Central Nervous System Vasculitis Associated with Lymphomas

9:00AM-11:00AM: Abstract Number: 2981

Prospective Cohort of Surgically-Diagnosed Aortitis at the Ottawa Hospital

9:00AM-11:00AM: Abstract Number: 2978

Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?

9:00AM-11:00AM: Abstract Number: 2943

Relationship Between Menstruation and Symptoms of Behcet’s Syndrome

9:00AM-11:00AM: Abstract Number: 2939

Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2942

Sequencing of 16S rRNA Reveals a Distinct Salivary Microbiome Signature in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 2949

Surgical Method for Aortic Root Involvement of Behcet Disease

9:00AM-11:00AM: Abstract Number: 2945

Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”

9:00AM-11:00AM: Abstract Number: 2964

Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients

9:00AM-11:00AM: Abstract Number: 2977

Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols

9:00AM-11:00AM: Abstract Number: 2944

Use of Muscle Biopsies for the Diagnosis of Systemic Vasculitis in a Rheumatology Service

9:00AM-11:00AM: Abstract Number: 2972

Vaccination and Risk of Childhood IgA Vasculitis (Henoch–Schönlein): A Case-Crossover Analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].